FibroBiologics, Inc. (FBLG) Price & Analysis

Compare

197 Followers

FBLG Stock Chart & Stats

$0.27

-$0.09(-3.98%)

At close: Jan 08 4:00 PM EST

$0.27

-$0.09(-3.98%)

Day’s Range― - ―

52-Week Range$0.24 - $2.79

Previous CloseN/A

Volume56.64K

Average Volume (3M)978.93K

Market Cap

$16.83M

Enterprise Value$25.97M

Total Cash (Recent Filing)$4.87M

Total Debt (Recent Filing)$7.11M

Price to Earnings (P/E)―

Beta0.59

Next Earnings

Apr 06, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding51,456,078

10 Day Avg. Volume1,423,641

30 Day Avg. Volume978,931

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)24.04

Price to Sales (P/S)0.00

P/FCF Ratio-5.44

Enterprise Value/Market Cap1.54

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-112.42

Enterprise Value/Ebitda-1.46

Forecast

1Y Price Target

$4.50

Price Target Upside1566.67% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Manufacturing PreparationThe company continues to make important progress advancing preparation for manufacturing the fibroblast-based spheroids candidate CYWC628 for the forthcoming Phase 1/2 trial in DFU patients.

Pipeline ProgressFibrobiologics continues to make progress across its pipeline, including advancing toward its Phase 1/2 study in diabetic foot ulcers and IND enabling studies in psoriasis.

Regulatory ComplianceThe expected completion of the manufacturing training runs for CYWC628 and confirmed manufacturing sterility by the end of 2025 is consistent with FDA cGMP.

Bears Say

Stock PerformanceThe stock has been down over -80% YTD, while the NBI is up over +20% YTD.

FibroBiologics, Inc. News

VTI ETF Daily Snapshot—12/01/2025

The Vanguard Total Stock Market ETF ($VTI) gives investors wide access to big, mid-sized, and small U.S. companies—essentially...

2h ago

FAT

HTZ

VTI ETF Daily Update — 11/28/2025

The Vanguard Total Stock Market ETF ($VTI) offers investors broad exposure to the entire U.S. equity market. In...

3d ago

DDS

FAT

VTI ETF Daily Update—11/27/2025

The Vanguard Total Stock Market ETF ($VTI) provides broad exposure to large-, mid-, and small-cap U.S. companies, giving...

4d ago

DDS

FAT

FibroBiologics announces payoff of outstanding debt

FibroBiologics (FBLG) has paid all amounts outstanding under the convertible promissory notes issued to YA II PN, pursuant...

5d ago

FBLG

VTI ETF Daily Update—11/25/2025

The Vanguard Total Stock Market ETF ($VTI) offers broad exposure to large-, mid-, and small-cap U.S. companies, giving...

6d ago

DDS

FAT

FibroBiologics prices 4.48M shares at 33.5c in registered direct offering

FibroBiologics (FBLG) entered into definitive agreements for the issuance and sale of an aggregate of 4,477,614 shares of...

7d ago

FBLG

VTI ETF Daily Update — November 21, 2025

The Vanguard Total Stock Market ETF ($VTI) offers broad exposure to large-, mid-, and small-cap U.S. companies, giving...

10d ago

DDS

LXP

FibroBiologics receives HREC approval for Phase 1/2 trial for CYWC628

FibroBiologics (FBLG) announced that it has received both public and private Human Research Ethics Committee, HREC, approvals in...

11d ago

FBLG

VTI ETF Daily Report—11/20/2025

The Vanguard Total Stock Market ETF ($VTI) provides broad exposure to large-, mid-, and small-cap U.S. companies, giving...

11d ago

LXP

VTI

FibroBiologics prices 3.54M shares at 33c in registered direct offering

FibroBiologics (FBLG) entered into a definitive agreement for the issuance and sale to an existing shareholder of 3,540,000...

12d ago

FBLG

VTI ETF Daily Report—11/19/2025

The Vanguard Total Stock Market ETF ($VTI) offers broad exposure to large-, mid-, and small-cap U.S. companies, giving...

12d ago

LXP

VTI

What’s Moving VTI ETF? Daily Snapshot — 11/18/2025

The Vanguard Total Stock Market ETF ($VTI) offers investors broad exposure to the entire U.S. equity market. In...

13d ago

LXP

VTI

FibroBiologics price target lowered to $5 from $10 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on FibroBiologics (FBLG) to $5 from $10 and keeps a Buy...

26d ago

FBLG

FibroBiologics Announces Securities Purchase Agreement

FibroBiologics, Inc. ( ($FBLG) ) just unveiled an announcement. On November 24, 2025, FibroBiologics, Inc. announced it entered...

6d ago

FBLG

FBLG FAQ

What was FibroBiologics, Inc.’s price range in the past 12 months?

FibroBiologics, Inc. lowest stock price was $0.24 and its highest was $2.79 in the past 12 months.

What is FibroBiologics, Inc.’s market cap?

FibroBiologics, Inc.’s market cap is $16.83M.

When is FibroBiologics, Inc.’s upcoming earnings report date?

FibroBiologics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 126 days.

How were FibroBiologics, Inc.’s earnings last quarter?

FibroBiologics, Inc. released its earnings results on Oct 31, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.01.

Is FibroBiologics, Inc. overvalued?

According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does FibroBiologics, Inc. pay dividends?

FibroBiologics, Inc. does not currently pay dividends.

What is FibroBiologics, Inc.’s EPS estimate?

FibroBiologics, Inc.’s EPS estimate is -0.1.

How many shares outstanding does FibroBiologics, Inc. have?

FibroBiologics, Inc. has 51,456,078 shares outstanding.

What happened to FibroBiologics, Inc.’s price movement after its last earnings report?

FibroBiologics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of FibroBiologics, Inc.?

Currently, no hedge funds are holding shares in FBLG

Company Description

FibroBiologics, Inc.

FibroBiologics, Inc. (FBLG) is a biotechnology company focused on developing and commercializing advanced cellular therapies that leverage fibroblast cells for regenerative medicine. The company operates in the biotechnology sector, emphasizing the development of therapies for various medical conditions, including chronic diseases and degenerative disorders. FibroBiologics aims to harness the therapeutic potential of fibroblasts to address unmet medical needs and improve patient outcomes.

FibroBiologics, Inc. (FBLG) Earnings & Revenues

Historic Earnings Reports

FBLG Stock 12 Month Forecast

Average Price Target

$4.50

▲(1566.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.39,0.7446153846153847,1.0992307692307692,1.453846153846154,1.8084615384615388,2.1630769230769236,2.517692307692308,2.8723076923076927,3.2269230769230774,3.5815384615384622,3.936153846153847,4.290769230769231,4.645384615384615,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.39,0.7061538461538461,1.0223076923076924,1.3384615384615386,1.6546153846153846,1.970769230769231,2.286923076923077,2.6030769230769235,2.9192307692307695,3.2353846153846155,3.551538461538462,3.867692307692308,4.1838461538461535,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.39,0.6676923076923077,0.9453846153846154,1.2230769230769232,1.5007692307692309,1.7784615384615385,2.056153846153846,2.333846153846154,2.6115384615384616,2.8892307692307693,3.166923076923077,3.4446153846153846,3.7223076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.62,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.62,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >